Effects of short-term subcutaneous administration of SMS 201-995 on calcitonin plasma levels in patients suffering from medullary thyroid carcinoma.
Guliana
J M
JM
INSERM U 113, Paris, France.
Guillausseau
P J
PJ
Caron
J
J
Siame-Mourot
C
C
Calmettes
C
C
Modigliani
E
E
D000293:Adolescent; D000328:Adult; D002116:Calcitonin / Q000097:blood*; D002277:Carcinoma / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000097:blood / Q000188:drug therapy*
D002116:Calcitonin; D015282:Octreotide